Table 8. The alteration frequency of a seven-gene signature (CAP2, CAP1, DSTN, CFL1 CFL2, ACTB, ACTG1) in cancers.

Cancer	Data source	N	Frequency (%)	Amplification (%N)	Deletion (%N)	Mutation (%N)	Multiple alterations (%N)
NEPC	Trento/Cornell/Broad 2016	107	40.2%	38.3% (41)		0.9% (1)	0.9% (1)
Pancrease	UTSW	109	38.5%	31.2% (34)	4.6% (5)	1.8% (2)	0.9% (1)
Ovarian	TCGA	311	32.5%	28.3% (88)	2.9% (9)	1% (3)	0.3% (1)
Bladder	TCGA 2014	127	29.9%	16.5% (21)		9.4% (12)	3.9% (5)
Bladder	TCGA 127	127	29.9%	17.3% (22)		7.9% (10)	4.7% (6)
CCLE	Novartis/ Broad 2012	881	24.1% (212)			4.1% (36)
Lung adeno	TCGA	230	29.9% (44)	17.3% (10)		7.9% (4)	4.7% (1)
Melanoma	TCGA	287	25.7%	19.1% (44)	4.3% (23)	0.4% (2)	1.7% (4)
Lung adeno	TCGA pub	230	25.4%	15.3%	0.7% ()	8% ()	1.4% ()
Esophagus	TCGA	184	25.2%	20.7% (38)	1.6% (3)	2.7% (5)
Ovarian	TCGA pub	316	25%	19.9% (63)	0.9% (3)	1.3% (4)
Lung Squ	TCGA	177	22%	14.1% (25)	1.7% (3)	5.6% (10)	0.6% (1)
Uterine	TCGA	242	21.9%	10.7% (26)	0.4 (1)	10.7 (26)
Stomach	TCGA pub	287	21.6%	9.1% (26)	4.5% (13)	6.6% (19)	1.4% (4)
Uterine	TCGA pub	240	20%	8.8% (21)	0.4% (1)	10.8% (26)